[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-peritoneal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-peritoneal-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,42,85,113,140,192,223,234,281,305,347,366,401,424,451,478,502,526,555,580,606,626,652,674],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054194","phase-2-igfbp-2-vaccine-to-prevent-ovarian-cancer-progression-in-patients-with-serologic-detection-of-recurrence-100054194",false,"NCT07495124","IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence","A Phase II Study of (IGFBP-2) Vaccine to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Have a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer who have received systemic chemotherapy including platinum-based chemotherapy\n* Have a cancer antigen 125 (CA-125) that normalized after first-line therapy\n* CA-125 increased to more than twice the upper limit of normal or two times the nadir value after most recent second or later line of treatment\n* Have no measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Ascites and pleural effusions are not measurable disease, if asymptomatic\n* All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study (end of one year follow up). Note: Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal\n* Have estimated life expectancy of at least 3 months\n* Be willing and able to provide written informed consent\u002Fassent for the trial\n* Be ≥ 18 years of age on day of signing informed consent\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale\n* White blood cell (WBC) ≥ 3000\u002Fmm\\^3 (performed within 14 days of treatment initiation)\n* Hemoglobin (Hgb) ≥ 10 g\u002Fdl (performed within 14 days of treatment initiation)\n* Hematocrit (Hct) ≥ 28% (performed within 14 days of treatment initiation)\n* Serum creatinine ≤ 2.0 mg\u002Fdl or creatinine clearance \\> 60 mL\u002Fmin (performed within 14 days of treatment initiation)\n* Total bilirubin ≤ 2.5 mg\u002Fdl (performed within 14 days of treatment initiation)\n* Aspartate aminotransferase (AST) ≤ 3 times upper limit of normal (ULN) (performed within 14 days of treatment initiation)\n* Blood glucose \\\u003C 1.5 ULN (performed within 14 days of treatment initiation)\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment (i.e., day 1)\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (if dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment\n\n  * Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune-related adverse events \\[irAEs\\]) is allowed\n* Has symptomatic ascites or pleural effusions\n* History of borderline or low malignant potential ovarian cancer\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., ≤ grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n* Has had prior chemotherapy, biologic therapy, targeted small molecule therapy, hormonal therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ≤ grade 1 or at baseline) from adverse events due to a previously administered agent\n\n  * Note: Patients with ≤ grade 2 neuropathy are an exception to this criterion and may qualify for the study\n  * Note: If a patient received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has an active infection requiring systemic therapy\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator\n* Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment\n* Clinically significant cardiovascular disease\n* Known severe hypersensitivity reactions to carboplatin ≥ grade 3, any history of anaphylaxis, or uncontrolled asthma\n* Patients with any contraindication to receiving recombinant human granulocyte macrophage-colony stimulating factor (rhuGM-CSF) based products\n* Has a known history of human immunodeficiency virus (HIV) (HIV 1\u002F2 antibodies)\n* Has known active hepatitis B (e.g., hepatitis B virus surface antigen \\[HBsAg\\] reactive) or hepatitis C (e.g., hepatitis c virus \\[HCV\\] ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected)\n* Has received a live vaccine or live-attenuated vaccine within 30 days of planned start of study therapy. Administration of killed vaccines is allowed\n\n  * Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed","FEMALE","18 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial studies how well giving the insulin-like growth factor binding protein 2 \\[pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)\\] vaccine after one dose of carboplatin works to stop ovarian cancer from growing, spreading, or getting worse (progressing) in patients whose cancer recurrence is detected only in the blood (serologic detection) following treatment with platinum chemotherapy. IGFBP-2 is a protein found in ovarian cancer cells. The IGFBP-2 vaccine may help the body build an effective immune response to kill tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It has been shown to activate parts of the immune system that may act against tumors. Giving the IGFBP-2 vaccine after a single dose of carboplatin may be an effective way to stop ovarian cancer from progressing in patients with serologic detection following treatment with platinum chemotherapy.",[26,27,28],"Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-10-01",{"date":37,"type":20},"2028-09-30",{"name":39,"class":40},"University of Washington","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100472291","a-study-comparing-perioperative-stress-reduction-vs-standard-of-care-in-ovarian-cancer-preserve-100472291","NCT05429970","A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study","Inclusion Criteria:\n\n* Advanced (stage II-IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma diagnosed on the basis of imaging, CA125, and clinical assessment\n* Scheduled to undergo exploratory laparotomy and PDS or IDS\n* Scheduled for surgery with at least 10 days of lead time, to allow the participant to take the β-blocker and COX2 inhibitor 7 days preoperatively\n* Age ≥18 years\n* ASA score of 1 to 3\n* Ability to understand the study objectives and procedures, comply with the protocol, and provide informed consent\n\nExclusion Criteria:\n\n* Chronic treatment with any β-blocker or COX inhibitor\n* Contraindication for β-blocker therapy (asthma, second- or third-degree atrioventricular block, sinus bradycardia, sick sinus syndrome, right-sided heart failure, pheochromocytoma, peripheral vascular disease)\n* Contraindication for COX2 inhibitor therapy (renal failure \\[creatinine level \\>1.5 mg\u002FdL\\], significant liver failure \\[known cirrhosis, bilirubin level \\>2\\], active peptic disease), or current use of oral anticoagulant)\n* Contraindication for regional epidural anesthesia\n* Chronic autoimmune disease\n* Active infection\n* Pregnant\n* Minimally invasive procedure\n* Participation in another clinical trial that interferes with this study",{"count":50,"type":20},35,[52],"NA","The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training\u002FMBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery\u002FPDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).",[55,27,56,57,58,59,60,61,62,63,64,65,66,28],"Ovarian Cancer","Stage II Ovary Cancer","Stage II Ovarian Cancer","Stage III Ovary Cancer","Stage III Ovarian Cancer","Stage IV Ovary Cancer","Stage IV Ovarian Cancer","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Stage II Fallopian Tube Cancer","Stage III Fallopian Tube Cancer","Stage IV Fallopian Tube Cancer",[68,69,70,71,72,73,62,63,28],"ovarian cancer","propranolol","etodolac","MBRT","mind-body resilience training","music therapy","RECRUITING","2026-06-30",{"date":77,"type":33},"2026-07-01",{"date":79,"type":33},"2022-06-17",{"date":81,"type":20},"2027-06-17",{"name":83,"class":40},"Memorial Sloan Kettering Cancer Center",7,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":108,"leadSponsor":110,"locationsCount":41},"100644807","phase-1-immu-132-in-trop-2-overexpressed-advanced-and-relapsed-ovarian-cancer-100644807","NCT07674615","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer","IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer: A Phases Ib, Single Arm Study","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years;\n* Histologically confirmed advanced or recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer;\n* Recurrent patients meeting one of the following two conditions:\n\nDisease recurrence or progression after at least one prior platinum-based chemotherapy regimen, with disease progression occurring less than 6 months from the last dose of platinum-based chemotherapy;\n\n* Disease recurrence or progression after at least three prior platinum-based chemotherapy regimens, with disease progression occurring ≥ 6 months from the last dose of platinum-based chemotherapy, and who are unable to receive standard platinum-based chemotherapy;\n* Patients with advanced epithelial ovarian cancer presenting with hematogenous metastasis, who are unable to receive standard treatment, with an estimated life expectancy of more than 3 months but approximately not exceeding 12 months with current therapy;\n* Have measurable disease per RECIST 1.1 criteria (Appendix A) or diagnosis of recurrence\u002Fdisease progression per GCIG criteria;\n* Known BRCA (Breast Cancer Gene) and HRD (Homologous Recombination Deficiency) status;\n* Have available paraffin-embedded or fresh tumor tissue for TROP-2 testing;\n* Tumor tissue TROP-2 H-score \\> 200;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n* Adequate bone marrow hematopoietic function and organ function, allowing the patient to receive treatment;\n* Patients must have had at least a 2-week interval from prior therapy (chemotherapy, investigational agents including small molecule inhibitors, endocrine therapy, immunotherapy, and\u002For radiotherapy) or major surgery;\n* Patients must have had at least a 2-week interval from high-dose systemic corticosteroids (however, low-dose corticosteroids \\\u003C 20 mg prednisone or its equivalent are permitted);\n* Patients must have recovered from acute toxicity due to prior therapy to Grade 1 or below;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients who have previously received topoisomerase I inhibitor therapy;\n* Patients with known hypersensitivity to the study drug, its metabolites, or formulation excipients;\n* Patients requiring ongoing treatment or prior use of any prohibited medications (e.g., UGT1A1 inhibitors);\n* Patients with Gilbert's syndrome;\n* Patients with other uncontrolled malignancies concurrently or within 5 years, whose treatment would interfere with the current therapy for recurrent ovarian cancer or affect the prognosis of this treatment. Carcinoma in situ and breast cancer (without active disease or signs of recurrence) are excluded;\n* Patients with a history of clinically significant hemorrhage, bowel obstruction, or gastrointestinal perforation within 6 months prior to the start of study treatment, with an estimated life expectancy of less than 3 months;\n* Patients with a history of significant cardiac disease within 6 months, such as uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure (NYHA Class III-IV), or clinically significant arrhythmias requiring antiarrhythmic therapy (except stable atrial fibrillation);\n* Patients with known clinically significant active chronic obstructive pulmonary disease (COPD) or other moderate-to-severe chronic respiratory disease within 6 months;\n* Patients with known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Patients with treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose, have all neurological symptoms returned to baseline, have no evidence of new or enlarging brain metastases, and are on a daily dose of ≤ 20 mg prednisone or its equivalent. All patients with carcinomatous meningitis are excluded regardless of clinical stability;\n* Patients with uncontrolled seizure history or active neurologic disorders; Patients with known HIV-1 or HIV-2 (or HIV-1\u002F2 antibody positive) with detectable viral load, or those taking medications that may interfere with SN-38 metabolism;\n* Patients with active HBV or HCV. For patients with a history of HBV or HCV, those with detectable viral load will be excluded;\n* Patients with known bleeding diathesis or active bleeding disorders;\n* Patients with active ≥ Grade 2 anorexia, nausea, or vomiting, and\u002For signs of bowel obstruction;\n* Patients with other concurrent medical or psychiatric conditions that, in the investigator's opinion, may confound study interpretation or prevent completion of study procedures and follow-up examinations;\n* Patients with any unstable medical problems (including the cardiac issues mentioned above, active treatment for symptomatic pulmonary embolism, stroke, renal or hepatic insufficiency, active infection\u002Fsepsis requiring intravenous antibiotics);\n* Any medical condition that, in the investigator's opinion, poses an undue risk to the patient's participation in the study.","80 Years",{"count":94,"type":20},19,[96],"PHASE1","To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.",[62,99,100,28],"Fallopian Tube Cancers","Primary",[102,103,104],"Ovarian cancer","TROP2","Antibody-drug conjugates","2026-06-28",{"date":75,"type":33},{"date":77,"type":20},{"date":109,"type":20},"2027-06-30",{"name":111,"class":112},"Shanghai Gynecologic Oncology Group","OTHER_GOV",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":84},"100586411","phase-3-phase-3-trial-evaluating-the-safety--efficacy-of-imnn-001-administered-in-combination-w-standard-nact--adjuvant-chemotherapy-in-newly-diagnosed-patients-w-advanced-eoc-fallopian-tube-or-primary-peritoneal-cancer-100586411","NCT06915025","Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w\u002F Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w\u002F Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w\u002F Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w\u002F Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","OVATION-3","Inclusion Criteria:\n\n1. Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.\n2. Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed epithelial pathologies), fallopian tube or peritoneal cancer that is Stage IIIB\u002FC or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.\n3. Participants eligible to receive neoadjuvant chemotherapy.\n4. Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of confirmed biomarker tumor status (HRD vs. HRP). See biomarker status definitions in the section below.\n5. Participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, participants must discontinue breastfeeding prior to study entry.\n6. Participants must have adequate:\n\n   1. Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500\u002Fµl. Exceptions may be made in patients with benign ethnic neutropenia \\>800\u002Ful with approval of a medical monitor. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000\u002Fµl.\n   2. Renal function: eGFR \\> 60 ml\u002Fmin\u002F1.73m2\n   3. Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN. Exceptions due to hepatic metastases can be considered in consultation with medical monitor.\n   4. Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1 as defined by CTCAE version 5.0.\n7. Participants must have an ECOG score of 0, 1 or 2.\n8. Participants should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within 4 weeks of study entry.\n9. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.\n\nExclusion Criteria:\n\n1. Participant who has received prior treatment with IMNN-001.\n2. Participant who has received oral or parenteral corticosteroids (\\>10 mg prednisone) within 2 weeks of first dose of IMNN-001 (if applicable) or who have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.\n3. Participant has mucinous, germ cell, transitional cell, clear cell, undifferentiated, or non-epithelial ovarian cancer.\n4. Participant has low-grade or Grade 1 epithelial ovarian cancer.\n5. Participant of childbearing potential, not practicing adequate contraception, participant who is pregnant, or participant who is breastfeeding are not eligible for this trial.\n6. Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, sub-occlusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n7. Participant has been diagnosed and\u002For treated with any therapy for invasive cancer \\\u003C3 years from study enrollment, completed adjuvant chemotherapy and\u002For targeted therapy at least 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.\n8. Participant with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, grade 1 or 2 Stage IA endometrioid endometrial cancer, or non-melanomatous skin cancer are allowed.\n9. Participant with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the participant to extreme risk or decreased life expectancy.\n10. Participant has known active hepatitis or HIV with detectable viral load.\n11. Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, IMNN-001, or their excipients.\n12. Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy).\n13. Participant is receiving treatment for active autoimmune disease. \"Active\" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.\n14. Participant who has received prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.\n15. Participant who has received prior chemotherapy for any abdominal or pelvic tumor is excluded. Participant may have received prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.\n16. Participant with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.\n17. Participant who will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded.\n18. Participant with any condition\u002Fanomaly that would interfere with the appropriate placement of the IP catheter for study drug administration including abdominal surgery within 4 weeks of study entry (for reason other than IP port placement or laparoscopic diagnosis of epithelial ovarian cancer), intestinal dysfunction as defined in #6 above.",{"count":122,"type":20},500,[124],"PHASE3","This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.",[62,55,63,28],[128,129,119],"IMNN-001","GEN-1","2026-06-01",{"date":132,"type":33},"2026-06-02",{"date":134,"type":33},"2025-07-09",{"date":136,"type":20},"2032-10-31",{"name":138,"class":139},"Imunon","INDUSTRY",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":148,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":167,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100483771","phase-1-rinatabart-sesutecan-rina-s-pro1184-gen1184-for-advanced-solid-tumors-gct1184-01-pro1184-001-100483771","NCT05579366","Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01\u002F PRO1184-001)","Phase 1\u002F2 Study of Rina-S in Patients With Locally Advanced and\u002For Metastatic Solid Tumors","RAINFOL-01","Inclusion Criteria:\n\nPart A and B:\n\n* Histologically or cytologically confirmed metastatic or unresectable solid malignancy including ovarian cancer (must have epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negative) (Part A), mesothelioma or cervical cancer (Part B).\n* Previously received therapies known to confer clinical benefit.\n* Measurable disease per RECIST v1.1 for all tumor types other than pleural mesothelioma which will use mRECIST v1.1 at baseline.\n\nPart C, E, and H:\n\nParticipants must have histologically or cytologically confirmed metastatic or unresectable epithelial ovarian cancer as specified below.\n\n* High grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (excluding endometrioid, clear cell carcinomas, mucinous, low grade, and those with a sarcomatous or neuroendocrine element)\n* Participants must have received up to 3 prior lines of therapy. Participants may have had up to to 4 prior lines of therapy are allowed if MIRV is locally approved and was used as the last line of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.\n* Participants must have platinum-resistant ovarian cancer.\n* Participants must have received prior bevacizumab or approved biosimilar.\n* Participants with known or suspected deleterious germline or somatic BRCA mutations (as determined by Food and Drug Administration \\[FDA\\]-approved test in a Clinical Laboratory Improvement Amendments \\[CLIA\\]-certified laboratory; or locally approved equivalent) and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment.\n* Measurable disease per the RECIST v1.1 at baseline.\n\nPart D:\n\nCohort D1:\n\n* Participants must have platinum-sensitive ovarian cancer.\n* Participants must have received 1 to 3 prior lines of therapy.\n\nCohort D2:\n\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Participants with primary platinum-refractory ovarian cancer must have received ≤2 prior lines of therapy. Primary platinum-refractory ovarian cancer is defined as a lack of response or by progression within 91 days after completing front-line platinum containing therapy.\n* Participants must have received 1 to 3 prior lines of therapy for platinum-resistant ovarian cancer (PROC), and up to 4 prior lines of therapy for platinum-sensitive ovarian cancer (PSOC). Prior treatments may have included bevacizumab, PARP inhibitor, and MIRV.\n\n  * Participants with PSOC must have disease progression on or after maintenance treatment, or at least 6 months (\\>183 days) or more from the last dose of platinum-based therapy.\n\nCohort D3:\n\n• Endometrial cancer (any subtype excluding sarcoma).\n\nCohort D4:\n\n• Primary advanced or recurrent endometrial cancer (any subtype excluding sarcoma and neuroendocrine tumors).\n\nPart F and G:\n\n* Participants must have histologically or cytologically confirmed EC.\n* Recurrent progressive EC (any subtype excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) following prior therapy.\n* Participants must have received 1 to 3 prior lines of therapy, and must have progressed radiographically on or after their most recent line of therapy:\n* Participants must have received prior platinum-based chemotherapy and a programmed death-ligand 1 (PD-\\[L\\])1 inhibitor.\n* Participants who progress \\>12 months after completion of prior adjuvant or neoadjuvant platinum-based chemotherapy must receive 1 additional cytotoxic systemic treatment prior to enrollment in this study.\n* Hormonal therapy alone (i.e., without chemotherapy) will not be counted as a separate line of therapy.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart I:\n\n* Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer (excluding clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies or low grade\u002Fborderline ovarian tumors).\n* Participants must have platinum sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart J:\n\n* Participants must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nPart K:\n\n* Participants must have histologically or cytologically confirmed metastatic or unresectable ovarian cancer (must have high grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer including serous, endometrioid, and clear cell carcinomas, and excluding mucinous, low grade, and those with a sarcomatous or neuroendocrine element).\n* Participants must have primary platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer.\n* Measurable disease per the RECIST Version 1.1 at baseline.\n\nExclusion Criteria:\n\n* History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids within the past 2 years, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n* Prior therapy with a topoisomerase 1 inhibitor-based antibody drug conjugate.\n\nNote: Other protocol-defined inclusion\u002Fexclusion may apply.","ALL",{"count":150,"type":20},884,[96,23],"This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.\n\nParticipants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).",[154,155,28,63,156,157,158,159,160,161,162,163,164,165,166],"High Grade Epithelial Ovarian Cancer","High Grade Serous Ovarian Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)","Mesothelioma","Breast Adenocarcinoma","Triple Negative Breast Cancer","Hormone Receptor-positive\u002FHer2 Negative Breast Cancer","Platinum-resistant Ovarian Cancer (PROC)","Platinum Sensitive Ovarian Cancer (PSOC)","Primary Refractory Ovarian Cancer","Uterine Cancer",[168,169,170,171,68,172,173,174,175,176,177,178,179,180,181,182],"antibody-drug conjugate","folate receptor alpha","folate receptor","solid tumor","primary peritoneal carcinoma","fallopian tube cancer","endometrial cancer","non-small cell lung cancer","mesothelioma","breast cancer","triple negative breast cancer","hormone receptor-positive (HR+)\u002Fhuman epidermal growth factor receptor 2 negative (HER2-) breast cancer","topoisomerase I inhibitor","PROC","epidermal growth factor receptor (EGFR)-mutated NSCLC",{"date":184,"type":33},"2026-06-03",{"date":186,"type":33},"2022-12-07",{"date":188,"type":20},"2027-10",{"name":190,"class":139},"Genmab",66,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":41},"100639206","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-pt2-100639206","NCT07617753","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","A Phase 1\u002F2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα\u002FFOLR1), and\u002For MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","DUAL-OV-CAR-NK","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function : ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures)\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's judgment, would increase risk (e.g., severe pulmonary disease) or interfere with study interpretation.","75 Years",{"count":202,"type":20},36,[96,23],"This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha\u002FFOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.",[62,28,26,206],"Recurrent or Refractory Disease After Standard Therapies",[208,209,210,211,212,213,214,102],"CAR-NK","Dual targeting","Mesothelin (MSLN)","Folate Receptor alpha","MUC16","Intraperitoneal administration","Adoptive cell therapy","2026-05-25",{"date":130,"type":33},{"date":218,"type":33},"2026-03-02",{"date":220,"type":20},"2028-03-17",{"name":222,"class":139},"Beijing Biotech",{"id":224,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":24,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":232,"leadSponsor":233,"locationsCount":41},"100631011",{"count":19,"type":20},[23],[26,27,28],"2026-05-22",{"date":230,"type":33},"2026-05-26",{"date":77,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":148,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":41},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":242,"type":20},27,[23],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[246,247,248,249,250,251,252,253,26,254,255,256,257,258,259,260,261,262,263,264,265,266,27,267,28,268,269,270,271],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Bladder Carcinoma","Breast Carcinoma","Cervical Carcinoma","Colorectal Carcinoma","Endometrial Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Head and Neck Carcinoma","Hematopoietic and Lymphatic System Neoplasm","Hepatocellular Carcinoma","Hodgkin Lymphoma","Lung Carcinoma","Malignant Solid Neoplasm","Mantle Cell Lymphoma","Melanoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Pancreatic Carcinoma","Prostate Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma","2026-05-15",{"date":274,"type":33},"2026-05-18",{"date":276,"type":33},"2025-12-18",{"date":278,"type":20},"2026-12-18",{"name":280,"class":40},"Mayo Clinic",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":41},"100332134","phase-1-serial-imaging-of-the-novel-radiotracer-18f-fluorthanatrace-18f-ftt-by-petctf-100332134","NCT03604315","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCTF","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCT","Inclusion Criteria:\n\n* History of known or suspected solid tumor.\n* At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], ultrasound, fludeoxyglucose \\[FDG\\] PET\u002FCT).\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \\\u003C 2 weeks prior to screening as standard of care.\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.",{"count":289,"type":20},300,[96],"This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)\u002Fcomputed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET\u002FCT uses a scanner to make detailed, computerized pictures of areas inside the body. PET\u002FCT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.",[250,26,27,28,293,294,295,296],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Solid Neoplasm","2026-04-10",{"date":299,"type":33},"2026-04-15",{"date":301,"type":33},"2018-12-18",{"date":109,"type":20},{"name":304,"class":40},"M.D. Anderson Cancer Center",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":313,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":317,"briefSummary":318,"conditions":319,"keywords":324,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100571905","risk-reducing-strategies-including-fimbriectomy-in-women-with-a-germline-mutation-predisposing-to-ovarian-or-pelvic-cancer-100571905","NCT06726330","Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer","Evaluation of Risk Control of Advanced Stage Tubo-ovarian or Primary Peritoneal Carcinoma Associated With Ovarian Carcinoma Risk-reducing Strategies, Including Fimbriectomy With Delayed Oophorectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer","FIMBRIMENOP","Inclusion Criteria:\n\n1. Woman between 35 to 50 years\n2. Addressed to or followed in an oncogenetic counselling\n3. Identified risk of tubo-ovarian or primary peritoneal carcinoma based on mutational status (BRCA1, BRCA 2, RAD51C, RAD51D, PALB2). The list of considered mutations may be extended during the study.\n4. Written informed consent\n5. Patient covered by the French \"Social Security\"\n\nExclusion Criteria:\n\n1. Prior bilateral oophorectomy and\u002For bilateral salpingectomy for any reason (prophylactic surgery or other)\n2. Personal history of ovarian, fallopian tube or primary peritoneal cancer\n3. Menopause defined by\n\n   • In women without prior chemotherapy If no prior hysterectomy: the absence of menses for at least 12 months, or FSH \\> 20 UI\u002FL with low estrogen level with no identified gynecological or endocrine explanation. Amenorrhea related to an intrauterine device, vaginal ring or estrogen-progestin pill will not be considered as menopause.\n\n   If prior hysterectomy: FSH \\>20 UI\u002FL with low estrogen level (with or without vasomotor symptoms, genitourinary symptoms)\n   * In women with prior chemotherapy: the absence of menses for at least 24 months\n   * In all women with progesterone-loaded intra-uterine device (IUD): FSH \\> 20 UI\u002FL with low estrogen level\n4. Inability to comply with medical follow-up of the trial (geographical, social or psychological reasons)\n5. Patient under guardianship or curatorship","35 Years","50 Years",{"count":316,"type":20},1100,[52],"• FIMBRIMENOP-2402 study aims to evaluate the long-term management of cancer risks in premenopausal women who have a genetic predisposition to tubo-ovarian or primary peritoneal carcinoma, such as mutations in BRCA1, BRCA2, RAD51C, RAD51D, or PALB2 genes. This study offers an alternative to standard preventive surgery (bilateral salpingo-oophorectomy or BSO) by exploring the use of fimbriectomy (removal of the fallopian tube's fimbria) followed by delayed oophorectomy (removal of ovaries at menopause).\n\nIt's a pragmatic multicenter trial conducted across various medical centers, employing a non-randomized controlled preference design to compare two preventive surgical strategies:\n\n1. Fimbriectomy followed by delayed oophorectomy (F-DO).\n2. Bilateral salpingo-oophorectomy (BSO).\n\nThe primary objective is to compare the long-term efficacy of two preventive surgical strategies :\n\n1. Fimbriectomy followed by delayed oophorectomy (F-DO).\n2. Bilateral salpingo-oophorectomy (BSO).\n\nAs for the design of the study, participants choose their preferred surgical strategy during or after oncogenetic counseling, ensuring patient autonomy in decision-making.\n\n• Follow-Up: Long-term follow-up includes clinical assessments, data collection from medical networks, and integration with national health databases to track outcomes up to the age of 70.\n\nThis is the first French comparative study in real-world settings and is classified as interventional research (RIPH1) under French regulations, given the need to validate fimbriectomy efficacy.",[320,321,322,323,28],"Tubo-ovarian Carcinoma","High-grade Serous Carcinoma","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV",[325,326,327,328,329,330,331,332,333,334,335,336],"Tubo-ovarian carcinoma","Primary peritoneal carcinoma","BRCA1\u002F2 mutations","RAD51C\u002FD mutations","PALB2 mutation","Preventive surgery","Fimbriectomy","Bilateral salpingo-oophorectomy","BSO","Cancer prevention","Premenopausal women","Genetic predisposition to cancer","2026-03-16",{"date":339,"type":33},"2026-03-17",{"date":341,"type":20},"2027-03",{"date":343,"type":20},"2071-03",{"name":345,"class":40},"Centre Oscar Lambret",23,{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":197,"acronym":198,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":353,"targetDuration":4,"studyType":21,"phases":354,"briefSummary":204,"conditions":355,"keywords":356,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":41},"100629921","phase-1-dual-targeting-car-nk-cells-for-recurrent-ovarian-cancer-msln-fr-muc16-100629921","NCT07480954","Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","Inclusion Criteria:\n\n* Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred).\n* Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated).\n* Measurable disease per RECIST v1.1.\n* Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy).\n* ECOG performance status 0-1.\n* Adequate organ function (example): ANC \\>= 1.0 x 10\\^9\u002FL; platelets \\>= 75 x 10\\^9\u002FL; hemoglobin \\>= 8 g\u002FdL; AST\u002FALT \\\u003C= 3 x ULN (\\\u003C= 5 x ULN with liver metastases); total bilirubin \\\u003C= 1.5 x ULN; creatinine clearance \\>= 50 mL\u002Fmin.\n* Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance).\n* Able to comply with study procedures and follow-up schedule; written informed consent.\n\nExclusion Criteria:\n\n* Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol).\n* Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy.\n* Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection.\n* Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening).\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III\u002FIV heart failure).\n* Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed).\n* Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period.\n* Major surgery within 4 weeks prior to lymphodepletion (except minor procedures).",{"count":202,"type":20},[96,23],[62,28,26,206],[208,209,210,211,357,213,214,102],"MUC16 (CA 125)","2026-03-14",{"date":360,"type":33},"2026-03-18",{"date":362,"type":33},"2026-02-04",{"date":364,"type":20},"2028-05-17",{"name":222,"class":139},{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":21,"phases":376,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":400},"100474599","phase-2-a-phase-ii-randomized-open-label-non-inferiority-study-of-niraparib-maintenance-after-3-vs-6-cycles-of-platinum-based-chemotherapy-in-completely-debulked-advanced-hrdpositive-high-grade-ovarian-cancer-patients-in-first-line-therapy-100474599","NCT05460000","A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy","A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)","N-Plus","Inclusion Criteria:\n\n1. Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.\n2. Female patient, age ≥ 18 years.\n3. FIGO Stage III-IV high-grade ovarian cancer (all histological types, except mucinous histology)\n4. Complete primary debulked patients (without any macroscopic residuals), confirmed by CT-Scan postoperatively.\n5. Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary cancer for central NGS analysis and must be HRDpositive defined as BRCAmut independent of NOGGO GIS Score OR NOGGO GIS Score \\>83 independent of BRCA status, based on these results.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n7. Patients must be able to take oral medications.\n8. Synchronous and secondary malignancies are allowed if the prognosis of the ovarian cancer is not affected. The investigator must contact the medical monitoring team before enrolling the patient in the clinical trial.\n9. Patients must have normal organ and bone marrow function:\n\n   1. Hemoglobin ≥ 10.0 g\u002FdL independent of transfusion ≤ 14 days prior to screening hemoglobin assessment\n   2. Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL\n   3. Platelet count ≥ 100 x 109\u002FL\n   4. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); \\\u003C 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome\n   5. Aspartate aminotransferase \u002FSerum Glutamic Oxaloacetic Transaminase (ASAT\u002FSGOT)) and Alanine aminotransferase \u002FSerum Glutamic Pyruvate Transaminase (ALAT\u002FSGPT)) ≤ 2,5 x ULN\n   6. Serum creatinine ≤ 1.5 x institutional ULN and creatinine clearance \\> 30 mL\u002Fmin.\n10. Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result ≤3 days prior to administration of the first dose of study treatment.\n\nPatients are considered to be of childbearing potential unless 1 of the following applies:\n\n1. Considered to be permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and\u002For bilateral oophorectomy; or\n2. Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 mIU\u002FmL or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state.\n\nFemale patients of reproductive potential must practice highly effective methods (failure rate \\\u003C 1% per year) of contraception with their partners, if of reproductive potential, during treatment and for 6 months following the last dose of chemotherapy or the last dose of niraparib, whichever occurs later, or longer if requested by local authorities. Highly effective contraception includes: Ongoing use of progesterone only injectable or implantable contraceptives; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal occlusion; Sexual abstinence as defined as complete or true abstinence, acceptable only when it is the usual and preferred lifestyle of the patient; periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not acceptable; or Sterilization of the male partner, with appropriate post-vasectomy documentation of absence of sperm in ejaculate.\n\nExclusion Criteria:\n\n1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e., germ cell tumors) and Ovarian tumors of low malignant potential (e.g., borderline tumors), or mucinous carcinoma of the ovary.\n2. Low-grade ovarian, fallopian tube or peritoneal cancer.\n3. Has known hypersensitivity to any of the study drugs or any of the excipients of any of the study drugs.\n4. Has known hypersensitivity to platin-containing compounds other than carboplatin.\n5. Patients posttransplant, including previous allogeneic bone marrow transplant.\n6. Has undergone interval debulking of the tumor.\n7. Has received any anti-cancer therapy for ovarian cancer other than primary surgery.\n8. Administration of other simultaneous chemotherapy drugs, any other anti-cancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).\n9. Has received prior treatment with a PARP inhibitor or has participated in a trial where any treatment arm included the administration of a PARP inhibitor.\n10. Bevacizumab is planned to be given together with first line chemotherapy or as maintenance.\n11. Clinically significant cardiovascular disease:\n\n    1. Cerebrovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment\n    2. Severe cardiac arrhythmia (recent event or active or uncontrolled)\n    3. New York Heart Association grade ≥2 congestive heart failure\n    4. Uncontrolled hypertension (defined as systolic blood pressure \\>140 mmHg and\u002For diastolic blood pressure \\>90 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy or posterior reversible encephalopathy syndrome\n    5. History of stroke or transient ischemic attack ≤6 months before start of study treatment\n    6. Coronary\u002Fperipheral artery bypass graft ≤6 months before start of study treatment\n    7. Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment\n12. History or evidence of brain metastases or spinal cord compression.\n13. Known history of MDS or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS\u002FAML.\n14. Current, clinically relevant bowel obstruction at the time of randomization.\n15. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n16. Pregnant or lactating women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (see inclusion criteria) starting with the screening visit through at least 6 months after the last dose of chemotherapy treatment or through at least 1 month after the last dose of niraparib, whichever occurs later.\n17. Participation in another clinical study with an investigational product immediately prior to randomization. Earliest time point for randomization is after the time required for the investigational product to undergo 5 half-lives has passed.\n18. Has a known history of Human Immunodeficiency Virus (HIV) infection (known HIV1\u002FHIV2 antibodies positive) or acquired immunodeficiency syndrome (AIDS) related illness.\n19. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] has been detected) infection.\n20. Has active infection with SARS-CoV-2 (antigen test).\n21. Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of chemotherapy treatment and while and 28 days after the last dose of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster, yellow fever, rabies, BCG, and typhoid vaccine. Administration of inactivated vaccines is allowed.\n22. Patient has contraindications listed in the most recent SmPC.\n23. Patient who might be dependent on the sponsor, CRO, site or the investigator.\n\n22\\. In Germany: Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40a S. 1 Nr. 2 AMG.",{"count":375,"type":20},640,[23],"Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.",[55,63,28,379],"Clear Cell Carcinoma",[381,382,383,384,385,386,387,388,389,390],"maintenance therapy","niraparib","HRDpositive","R0","primary tumor debulking","chemotherapy","LOH","carboplatin","paclitaxel","first line","2026-02-11",{"date":393,"type":33},"2026-02-12",{"date":395,"type":33},"2024-10-11",{"date":397,"type":20},"2032-10-01",{"name":399,"class":40},"North Eastern German Society of Gynaecological Oncology",47,{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":410,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":41},"100094359","data-collection-for-patients-with-low-grade-ovarian-or-peritoneal-tumors-100094359","NCT00488878","Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors","Data Collection for Patients With Low Grade Ovarian Carcinoma","Inclusion Criteria:\n\n* Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis:\n\n  * Ovarian tumor of low malignant potential\n  * Low-grade serous carcinoma of the ovary\n  * Primary peritoneal tumor of low malignant potential\n  * Low-grade serous carcinoma of the peritoneum\n  * Psammocarcinoma",{"count":409,"type":20},2000,"OBSERVATIONAL","This study collects information to maintain a database on patients with low-grade ovarian or peritoneal tumors. Collecting information about the type of cancer and treatment, as well as details about follow-up care, may help researchers learn and better understand these tumor types and help develop better treatments for them.",[413,414,27,28,415,416],"Low Grade Ovarian Serous Adenocarcinoma","Malignant Ovarian Neoplasm","Primary Peritoneal Low Grade Serous Adenocarcinoma","Psammocarcinoma",{"date":418,"type":33},"2026-02-13",{"date":420,"type":33},"2006-05-19",{"date":422,"type":20},"2035-05-01",{"name":304,"class":40},{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":436,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":450},"100552145","phase-1-a-study-to-learn-if-27t51-a-mucin-16-muc16-protein-targeting-immune-cell-therapy-administered-alone-or-in-combination-is-safe-and-how-well-it-works-for-adult-participants-with-recurrent-or-treatment-resistant-ovarian-cancers-100552145","NCT06469281","A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","A Phase 1a\u002F1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Key Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 classification\n3. Recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol\n4. Serum cancer antigen (CA) 125 ≥ 2 × upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening\n5. Participants must have at least 1 measurable tumor lesion as defined by the response evaluation criteria in solid tumors (RECIST) 1.1.\n6. Expected survival ≥ 3 months\n\nKey Exclusion Criteria:\n\n1. Inadequate cardiovascular, renal and hepatic function, as described in the protocol\n2. Absolute lymphocyte count (ALC) \\\u003C 100 cells\u002FμL at time of leukapheresis\n3. History of Grade ≥ 2 hemorrhage within 30 days, or inadequate coagulation parameters, as described in the protocol\n4. Known history or presence of clinically relevant central nervous system (CNS) pathology, as described in the protocol\n5. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune related adverse events (AEs)\n6. Treatment with any cellular or gene therapy\n\nNote: Other protocol-defined Inclusion\u002FExclusion criteria apply",{"count":432,"type":20},90,[96],"This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer.\n\nThis study has two (2) major parts:\n\nPhase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51.\n\nInformation collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.",[62,28,63],[55,437,438,439,212,440],"CAR T","Peritoneal","Fallopian Tube","Immunotherapy","2026-01-30",{"date":443,"type":33},"2026-02-03",{"date":445,"type":33},"2024-08-06",{"date":447,"type":20},"2030-05-27",{"name":449,"class":139},"Regeneron Pharmaceuticals",5,{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":458,"targetDuration":4,"studyType":410,"phases":4,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":4},"100613667","impact-of-dietary-patterns-on-prognosis-of-ovarian-cancer-patients-during-parpi-maintenance-100613667","NCT07269574","Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance","A Multicenter, Retrospective Clinical Study Evaluating the Effect of Different Dietary Patterns on the Prognosis of Ovarian Cancer Patients During PARPi Maintenance Therapy","Inclusion Criteria:\n\n* Female patients aged 18 to \\\u003C75 years.\n* Histologically or cytologically diagnosed with primary high-grade serous ovarian cancer (HGSOC), fallopian tube cancer, or primary peritoneal cancer.\n* Received initial tumor cytoreductive surgery (Primary Debulking Surgery or Interval Debulking Surgery) and first-line platinum-based chemotherapy, achieving Complete Response (CR) or Partial Response (PR).\n* Received PARP inhibitors as maintenance therapy for the first time following the completion of first-line treatment.\n* Complete clinical data available in the electronic medical records, including baseline characteristics, first-line treatment details, PARPi maintenance therapy information, and prognostic follow-up data.\n* The patient (or primary caregiver) has normal communication abilities, voluntarily agrees to participate, and is able to cooperate in completing the retrospective Food Frequency Questionnaire (FFQ).\n\nExclusion Criteria:\n\n* Clinical diagnosis only, without pathological or cytological confirmation.\n* Non-high-grade serous histological subtypes (e.g., ovarian clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, low-grade serous carcinoma).\n* Secondary or metastatic ovarian cancer (malignancy originating from other organs).\n* Severe deficiency of key clinical or prognostic information that prevents assessment of the primary endpoint.\n* Inability to accurately recall dietary information due to cognitive impairment, mental illness, or other reasons.\n* Presence of severe metabolic or digestive system diseases during PARPi maintenance therapy that required specific restricted diets (e.g., insulin-dependent diabetes, dialysis-dependent renal insufficiency, short bowel syndrome, active Crohn's disease).\n* Occurrence of significant physiological events during the study period that significantly altered dietary structure (e.g., major gastrointestinal surgery).",{"count":459,"type":20},600,"The goal of this retrospective observational study is to evaluate the relationship between different dietary patterns (specifically low-carbohydrate diets) and the prognosis of patients with high-grade serous ovarian cancer (HGSOC) receiving first-line PARP inhibitor (PARPi) maintenance therapy. The main questions it aims to answer are:\n\n* Is there an association between dietary patterns and patients' Progression-Free Survival (PFS)?\n* Is there an association between dietary patterns and Overall Survival (OS)? This is a multicenter, retrospective cohort study. Researchers will review electronic medical records from 14 tertiary hospitals in China to identify women who received first-line PARP inhibitor maintenance for advanced high-grade serous ovarian cancer between 2020 and 2025, and collect information on baseline characteristics, treatments and follow-up outcomes.\n\nResearchers will compare patients with a \"low-carbohydrate diet pattern\" to those with a \"regular\u002Fhigh-carbohydrate diet pattern\" to see if there are differences in treatment outcomes and survival.\n\nParticipants will:\n\n* Have their clinical, pathological, and treatment data collected from electronic medical records.\n* Complete a retrospective Food Frequency Questionnaire (FFQ) via phone or clinic visit to recall their dietary habits during the maintenance treatment period.\n* Optionally provide a blood sample for nutrition and metabolic analysis. (For participants at the main study center only) No experimental drugs or specific diets will be given in this study. All anti-cancer treatments are decided by the treating physicians as part of routine clinical care.",[55,99,28,462],"High-grade Serous Ovarian Cancer",[55,464,465,466,467,468],"High-Grade Serous Ovarian Cancer","PARP Inhibitor","Maintenance Therapy","Dietary Pattern","Low-Carbohydrate Diet","2025-11-26",{"date":471,"type":33},"2025-12-08",{"date":473,"type":20},"2025-11-27",{"date":475,"type":20},"2026-12-31",{"name":477,"class":40},"Tongji Hospital",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":485,"targetDuration":4,"studyType":21,"phases":487,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":41},"100457445","survival-effect-of-hepato-celiac-lymphadenectomy-in-primary-or-relapsed-ovarian-cancer-100457445","NCT05236686","Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer","A Prospective, Multi-center, Single-Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Hepato-celiac Lymphadenectomy in the Treatment of Advanced and Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Age ≥18 years to ≤ 75 years.\n* Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum sensitive, relapsed EOC, PPC or FTC (no more than 4 lines of therapy)\n* Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings\n* Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation\n* 1 to 3 episodes of neoadjuvant chemotherapy is allowed in primary settings\n* Platinum sensitive relapse is defined as those with platinum-free interval of 6 months or more.\n* ASA score of 1 to 2\n* ECOG performance status of 0 to 2\n* Adequate bone marrow, liver and renal function to receive chemotherapy and subsequently to undergo surgery:\n* White blood cells \\>3,000\u002FµL, absolute neutrophil count ≥1,500\u002FµL, platelets ≥100,000\u002FµL, hemoglobin ≥9 g\u002FdL,\n* Serum creatinine \\\u003C1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL\u002Fmin according to Cockcroft-Gault formula or to local lab measurement\n* Serum bilirubin \\\u003C1.25 x UNL, AST(SGOT) and ALT(SGPT) \\\u003C2.5 x UNL\n* Comply with the study protocol and follow-up.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Patients with non-epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma.\n* Low-grade carcinoma.\n* Mucinous ovarian cancer.\n* Infeasible complete resection according to preoperative evaluation\n* Unresectable pulmonary and hepatic parenchymal metastases, multiple thoracic lymph nodes metastases, brain or bone metastases according to preoperative evaluation.\n* Carcinomatosis on small bowel mesentery or intestinal wall by surgical findings and infeasible optimal surgery by bowel resection or peritonectomy.\n* Progression after neoadjuvant chemotherapy in primary settings.\n* Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or breast cancer (without any signs of relapse or activity).\n* Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol.\n* Other conditions, such as religious, psychological and other factors, that could interfere with provision of informed consent, compliance to study procedures, or follow-up.",{"count":486,"type":20},94,[52],"The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.",[62,63,28],[55,491,492,493],"Surgery","Lymph Node Metastasis","Hepato-celiac Lymphadenectomy","2025-11-16",{"date":496,"type":33},"2025-11-19",{"date":498,"type":33},"2022-02-15",{"date":500,"type":20},"2025-12",{"name":111,"class":112},{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":21,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":525},"100553898","phase-2-cryocompression-with-or-without-cilostazol-for-the-prevention-of-paclitaxel-induced-neuropathy-in-patients-with-gynecological-cancers-100553898","NCT06492070","Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers","Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol","Inclusion Criteria:\n\n* INCLUSION CRITERIA FOR ARMS A and B:\n* Age 18 years or older\n* Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and planned chemotherapy regimen of 6-9 cycles of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy\n* Eastern Cooperative Oncology Group performance status from 0 to 2\n* ARM C: Age 18 years or older\n* ARM C: Diagnosis of uterine, ovarian\u002Ffallopian tube\u002Fprimary peritoneal, cervical, or vulvar cancer and completion of 6-9 cycles of a chemotherapy regimen consisting of paclitaxel and carboplatin or cisplatin with or without VEGF inhibition, with or without immunotherapy, and with or without HER2-directed therapy within the last 3 months\n* ARM C: Eastern Cooperative Oncology Group performance status from 0 to 2\n\nExclusion Criteria:\n\n* EXCLUSION CRITERIA FOR ARMS A and B:\n* Any patient unable and\u002For unwilling to cooperate with all study protocols\n* Previous treatment with paclitaxel\n* Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* Diabetes mellitus with hemoglobin A1c \\>7.0\n* Hepatic impairment, moderate to severe (Class B \\& C by Child-Pugh score)\n\n  * Slight or moderate malignant ascites alone will not be considered indicative of hepatic impairment in the absence of other evidence of hepatic disease\n* Raynaud's phenomenon\n* Active wounds on the hands or feet\n* High risk uncontrolled arrhythmias\n* Ischemic heart disease\n* Inadequate bone marrow function with white blood count \\\u003C 4,000\u002Fmm\\^3 and platelet count \\\u003C 100,000\u002Fmm\\^3\n* Inadequate liver function with serum total bilirubin \\>= 1.5mg\u002FdL\n* Inadequate renal function with serum creatinine \\>= 1.5mg\u002FdL\n* On one or more antiplatelet therapies excluding acetylsalicylic acid\n* Hypersensitivity (e.g. anaphylaxis, angioedema) to cilostazol or any components of cilostazol\n* Pregnant and nursing patients\n\n  * Patients enrolled in this study who have the potential to become pregnant (have an intact uterus, ovary(ies), and fallopian tube(s), have not entered menopause, and have regular menses) are required to utilize reliable contraception such as celibacy, hormonal contraception (oral pills, implant, injection, ring or patch), intrauterine device (IUD), condom and\u002For diaphragm with spermicide\n* Incarcerated patients\n* Patients unable to consent for themselves, due to cognitive impairment or other reason\n* Patients with contraindications to cilostazol\n* Any patient who does not meet criteria to receive chemotherapy\n* ARM C: Any patient unable and\u002For unwilling to cooperate with all study protocols\n* ARM C: Previous treatment with paclitaxel\n* ARM C: Patients with baseline pre-chemotherapy neuropathy requiring pharmacologic treatment\n* ARM C: Diabetes mellitus with hemoglobin A1c \\>7.0\n* ARM C: Pregnant patients\n* ARM C: Incarcerated patients\n* ARM C: Patients unable to consent for themselves, due to cognitive impairment or other reason",{"count":510,"type":20},70,[23],"The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.",[251,26,261,514,27,28,515],"Malignant Uterine Neoplasm","Vulvar Carcinoma","2025-08-20",{"date":518,"type":33},"2025-08-27",{"date":520,"type":33},"2024-08-01",{"date":522,"type":20},"2027-12-31",{"name":524,"class":40},"Emory University",3,{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":21,"phases":536,"briefSummary":537,"conditions":538,"keywords":539,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":554},"100594748","phase-2-personalized-timing-of-interval-debulking-surgery-in-advanced-ovarian-cancer-100594748","NCT07023484","Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer","Personalized Timing of Interval Debulking Surgery Based on KELIM After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer - a Multicenter Randomized Phase II Non-inferiority Trial (PRESELECT-I Trial)","Preselect-1","Inclusion Criteria:\n\n1. Patients aged 18 years old or older\n2. Patients with Eastern Cooperative Oncology Group score 0-1 within 28 days prior to recruitment\n3. Patients who can sign the informed consent\n4. Patients with stage III-IV histologically or cytologically confirmed epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer not amenable for PDS\n5. Patients who have baseline computed tomography (CT) of thorax, abdomen and pelvis.\n6. Patients who are planned for neoadjuvant chemotherapy (NACT) using 3-weekly carboplatin and paclitaxel. Those who have received one cycle of NACT may be eligible if the CA125 schedule of the study group can be matched.\n7. Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal)\n8. Patients who agree for chemotherapy and interval debulking surgery (IDS) if the disease becomes operable after NACT\n9. Patients with adequate hematologic, liver and renal functions for chemotherapy\n10. Patients who agree to receive adjuvant chemotherapy after IDS. The total number of NACT and adjuvant chemotherapy should be four or above, up to maximum of 9 cycles.\n11. Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment.\n12. Patients must have either germline and \u002F or somatic BRCA test, or homologous recombination deficiency (HRD) test.\n\nExclusion Criteria:\n\n1. Patients who have borderline malignancy, or non-EOC like germ cell or sex cord tumor, or metastatic diseases from other origins\n2. Patients with mucinous and neuroendocrine histology\n3. Patients with history of other malignancies within five years\n4. Patients who are eligible for primary debulking surgery (PDS)\n5. Patients who cannot undergo PDS because of parametrial and\u002For vaginal involvement alone\n6. Patients who are not fit for PDS because of medical morbidities or refusal of operation\n7. Patients who have already started NACT outside the study centers, except those who have received only one cycle within 7 days and the baseline CA125 value within 3 days of NACT (normal cut-off 35 U\u002Fml) is available\n8. Patients who participate in other interventional studies\n9. Patients who are pregnant or breastfeeding\n10. Patients who have contraindications to platinum-based chemotherapy\n11. Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.",{"count":535,"type":20},126,[23],"About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.",[55,63,28],[540,68,173,541,542,543,544],"advanced","primary peritoneal cancer","neoadjuvant chemotherapy","interval debulking surgery","kelim","2025-06-29",{"date":547,"type":33},"2025-07-02",{"date":549,"type":33},"2025-05-22",{"date":551,"type":20},"2028-12-31",{"name":553,"class":40},"The University of Hong Kong",6,{"id":556,"slug":557,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":562,"targetDuration":4,"studyType":21,"phases":564,"briefSummary":565,"conditions":566,"keywords":567,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":579},"100562353","phase-1-surgery-for-relapsed-ovarian-cancer-in-precision-100562353","NCT06602063","Surgery for Relapsed Ovarian Cancer in Precision","Surgery With ICBs in BRCAwt, CD8+ TILs, 1st Relapsed Ovarian Cancer: A Pilot Study","Inclusion Criteria:\n\n* Arm 1 (criteria-fulfilled, CF)\n\n  1. Age at recurrence ≥ 18 years, \\\u003C80 years.\n  2. Patients with platinum-sensitive, first relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (EOC, PPC, FTC), which is defined as those with treatment -free interval of 6 months or more.\n  3. If the patient had previous PARPi maintenance therapy, disease progression should occurring at lease 3 months after the prior PARPi withdrawal.\n  4. BRCA1\u002F2 wild type (both germline and somatic)\n  5. Homologous Recombination Deficiency (HRD) is available\n  6. Patients must provide archived or fresh tumor tissue samples for biomarker detection.\n  7. PD-L1 positive (if either at least 1% of assessed tumour cells expressed membranous PD-L1, at least 5% of immune cells within the tumour area expressed PD-L1, or both) and number of intraepithelial CD8+ tumor-infiltrating lymphocytes (TILs) per high-powered field ≥ 6.\n  8. Assessed by the experienced surgeons, complete resection of all recurrent disease is possible (predicted by iMODEL score or by PET\u002FCT).\n  9. ECOG performance status of 0 to 2\n  10. Adequate bone marrow, liver, and renal function to receive combined immunotherapy\n  11. Written informed consent\n* Arm 2 (compassionate use, CU), Similar to cohort 1, except for:\n\n  1. If the patient had previous PARPi maintenance therapy, disease progression should occurring within 3 months after the prior PARPi withdrawal or during the PARPi maintenance therapy.\n  2. PD-L1 positive or number of intraepithelial CD8+ TILs per high-powered field ≥ 6.\n* Arm 3 (real word) Patients who meet the inclusion criteria but refuse to participate in the phase II CF and CU cohorts.\n\nExclusion Criteria:\n\n1. Patients with borderline, low-grade tumors, clear cell carcinoma, as well as non-epithelial tumors.\n2. Patients with platinum-resistant or refractory diseases.\n3. Lack of tumor samples (archived and\u002For recently obtained) for biomarker detection.\n4. Previous administration of immunotherapy\n5. Patients have been vaccinated with the live vaccine or received anti-tumor treatment within 4 weeks before the first administration.\n6. Synchronous or metachronous (within 5 years) malignancy, symptomatic or uncontrolled visceral metastases that require simultaneous treatment, other than carcinoma in situ or breast cancer (without any signs of relapse or activity).\n7. Patients with parenchymal metastases and life-threatening complications in short term.\n8. Any other concurrent medical conditions contraindicating surgery, chemotherapy, or immunotherapy that could compromise the adherence to the protocol.\n9. Patients are known to be allergic to the active ingredients or excipients of Sintilimab.\n10. HRD status is not available.\n11. Any medication induced considerable risk of surgery, e.g. estimated bleeding due to oral anticoagulating agents or bevacizumab.\n12. Patients for interval-debulking, or for second-look surgery, or palliative surgery planned.\n13. Impossible to assess the resectability of recurrent disease or evaluate the score. Radiological signs suggesting complete resection is impossible.",{"count":563,"type":20},33,[96,23],"This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1\u002FCTLA-4 bispecifics therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC).",[62,63,28],[102,568,569,570],"Immune checkpoint inhibitor","Secondary cytoreduction","Biomarker-driven","2025-06-24",{"date":573,"type":33},"2025-06-27",{"date":575,"type":20},"2025-07",{"date":577,"type":20},"2030-06",{"name":111,"class":112},2,{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":21,"phases":589,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":605},"100454647","phase-2-surgery-combined-with-maintenance-targeted-therapy-in-the-treatment-of-advanced-ovarian-cancer-100454647","NCT05200260","Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","A Prospective, Multicenter, Randomized Phase II Trial on Optimal Timing of Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","Inclusion Criteria:\n\n* Females aged ≥ 18 years.\n* Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma\n* Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET\u002FCT examination\n* Complete cytoreduction can be achieved based on CT or PET\u002FCT examination\n* Patients must agree to undergo BRCA (breast cancer gene) and HRD (homologous recombination deficiency) testing\n* Performance status (ECOG 0-2)\n* Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery:\n\n  1. white blood cells \\>3,000\u002FµL, absolute neutrophil count ≥1,500\u002FµL, platelets ≥100,000\u002FµL, hemoglobin ≥9 g\u002FdL,\n  2. serum creatinine \\\u003C1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL\u002Fmin according to Cockroft-Gault formula or to local lab measurement,\n  3. serum bilirubin \\\u003C1.25 x UNL, AST(SGOT) and ALT(SGPT) \\\u003C2.5 x UNL.\n* Comply with the study protocol and follow-up.\n* Patients who have given their written informed consent.\n\nExclusion Criteria:\n\n* Non-epithelial ovarian malignancies and borderline tumors\n* Low grade ovarian cancer\n* Mucinous ovarian cancer\n* Complete cytoreduction cannot be achieved according to preoperative evaluation, including pulmonary and hepatic parenchymal metastases, unresectable extensive pleural metastases, multiple thoracic lymph nodes metastases, brain or bone metastases\n* Patient has a known hypersensitivity to the components of olaparib\u002Fbevacizumab or its excipients\n* Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ, thyroid carcinoma, or breast carcinoma (without any signs of relapse or activity, early-stage).\n* Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise adherence to the protocol.\n* Other conditions, such as religious, psychological, and other factors, that could interfere with the provision of informed consent, compliance to study procedures, or follow-up.",{"count":588,"type":20},220,[23],"Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer",[55,63,28],[55,593,594,595,596],"Primary Debulking Surgery","Neoadjuvant chemotherapy","Poly-adenosine Ribose Phosphate Inhbitors (PARPi)","Bevacizumab","2025-02-06",{"date":599,"type":33},"2025-02-10",{"date":601,"type":33},"2022-07-13",{"date":603,"type":20},"2027-06",{"name":111,"class":112},9,{"id":607,"slug":608,"hasResults":11,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":613,"targetDuration":4,"studyType":21,"phases":615,"briefSummary":616,"conditions":617,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":622,"leadSponsor":624,"locationsCount":41},"100548436","phase-2-rc48-treatment-for-platinum-sensitive-recurrent-ovarian-cancer-with-her2-expression-100548436","NCT06420973","RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression","A Single-arm, Multicenter, Phase II Study of RC48 Plus Platinum With or Without Bevacizumab in the Treatment of HER-2 Expression Platinum-Sensitive Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Female subjects aged from 18 to 75 years old;\n* Pathology confirmed the diagnosis of primary epithelial ovarian\u002Ffallopian tube\u002Fperitoneal carcinoma;\n* Previous treatment lines ≥1 and ≤4, first-line treatment may include maintenance therapy after complete clinical or pathological response;Previously not receiving targeted HER2 drug therapy (including monoclonal antibodies and ADC drugs)\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;\n* Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1);\n* Estimated life expectancy of more than 3 months;\n* Local laboratory confirmed HER2 expression: IHC 1+, 2+, or 3+; Subjects were able to provide samples of the primary or metastatic site of the tumor for HER2 detection（Paraffin blocks, paraffin embedded sections or fresh tissue sections ）\n* Adequate haematological, hepatic and renal functions defined by the protocol;\n* Negative blood pregnancy test at Screening for women of childbearing potential; Highly effective contraception for female subjects if the risk of conception exists;\n\nExclusion Criteria:\n\n* The pathological type is non epithelial ovarian\u002Ffallopian tube\u002Fperitoneal cancer or metastatic ovarian cancer;\n* The patient has ≥ grade 2 peripheral neuropathy;\n* Patients with active bleeding or pathological conditions with high risk of bleeding, such as known hemorrhagic diseases, coagulation disorders, or tumors involving large blood vessels;\n* Suffering from central nervous system metastasis and\u002For cancerous meningitis. Except for stable brain metastases; 5.The toxicity caused by previous anti-tumor treatments has not yet recovered to CTCAE (version 5.0) level 0-1 (excluding 2nd degree hair loss);\n* Patients who require parenteral hydration or nutrition and have evidence of partial intestinal obstruction or perforation;\n* Except for patients with primary endometrial cancer or a history of primary endometrial cancer, unless all of the following conditions are met: stage not greater than I-B stage; No more than superficial muscle infiltration, no vascular or lymphatic infiltration; No poorly differentiated subtypes, including papillary fluid, clear cells, or other FIGO grade 3 lesions;\n* For patients undergoing cell reduction surgery before treatment, if combined with bevacizumab, they must wait for at least 28 days before starting the treatment with bevacizumab;\n* Have undergone major surgery within 4 weeks prior to the start of study administration and have not fully recovered;\n* A large amount of pleural or ascitic fluid accompanied by clinical symptoms or requiring symptomatic treatment;\n* Within 30 days of initial medication or expected to receive attenuated live vaccines during the study period;\n* Serious arterial\u002Fvenous thrombotic events or cardiovascular and cerebrovascular accidents that occurred within one year prior to drug administration were studied;\n* There are systemic diseases that have not been controlled stably according to the judgment of the researcher, including diabetes, liver cirrhosis (Child Pugh Class B or C), interstitial pneumonia, obstructive pulmonary disease, etc;\n* Clinically significant cardiovascular disease patients(According to the specific requirements of the plan);\n* Individuals with active autoimmune diseases or immunodeficiency, or a history of the aforementioned conditions, including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, pituitary inflammation, vasculitis, nephritis, etc., shall not be included. The following exceptions apply: Patients with a history of autoimmune hypothyroidism who have received thyroid hormone replacement therapy may be included in the study. Patients with type 1 diabetes whose blood sugar can be controlled after treatment with insulin administration scheme can participate in this study;\n* Subjects with a history of other malignant tumors within five years (excluding complete treatment for in situ cervical cancer, basal cell carcinoma, or squamous cell carcinoma skin cancer);\n* Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 2000 IU \u002F ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;\n* Severe infection (e.g. need for intravenous antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or fever (\\>38.5%) of unknown reason occurred during the screening period\u002Fbefore the first administration；\n* Currently participating in intervention clinical research treatment, or receiving other investigational drugs or research instruments within 4 weeks prior to the first administration; Not fully recovered from toxicity and\u002For complications caused by any intervention measures prior to initial administration (i.e. ≤ level 1 or reaching baseline, excluding fatigue or hair loss);\n* Has a clear history of allergies and may have potential allergies or intolerance to the investigational drug and its similar biological agents;\n* Individuals with a history of abuse of psychotropic substances who are unable to quit or have mental disorders;",{"count":614,"type":20},54,[23],"The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.",[27,26,28],"2024-05-16",{"date":620,"type":33},"2024-05-20",{"date":618,"type":20},{"date":623,"type":20},"2027-09-17",{"name":625,"class":40},"Peking University Cancer Hospital & Institute",{"id":627,"slug":628,"hasResults":11,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":633,"targetDuration":4,"studyType":21,"phases":635,"briefSummary":636,"conditions":637,"keywords":639,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":450},"100361213","phase-2-surgery-and-niraparib-in-secondary-recurrent-ovarian-cancer-soc-3-trial-100361213","NCT03983226","Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)","A Phase II, Randomized Study of Cytoreductive Surgery Combined With Niraparib Maintenance in Platinum-sensitive, Secondary Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Age ≥18 years to ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Patients with platinum-sensitive, secondary relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer.\n* Front-line or second-line treatment may have included maintenance therapy (i.e. bevacizumab, PARP inhibitor)\n\n  * Cohort 1 and Cohort 3: No prior use of PARP inhibitor.\n  * Cohort 2: Prior use of PARP inhibitor.\n  * Cohort 3: No prior use of PARP inhibitor.\n* Secondary cytoreductive surgery (SCR) when first recurrence\n\n  * Cohort 1 and Cohort 2: Never received SCR\n  * Cohort 2: Never received SCR\n  * Cohort 3: Received SCR\n* Assessed by the experienced surgeons, complete resection of all recurrent disease is possible. Single or localized lesions identified by CT, or MRI, or positron emission tomography\u002Fcomputed tomography (PET\u002FCT). PI and Co-PI reach consensus if extensive lesions or carcinomatosis.\n* It can be included if single lesion outside the peritoneal cavity can be resected.\n* No more than 3 disease lesions by central-reviewed PET\u002FCT imaging if the participated center has never participated in any surgical trials on ovarian cancer before.\n* Patients who have given their signed and written informed consent and their consent.\n\nExclusion Criteria:\n\n* Patients with borderline tumors as well as non-epithelial tumors.\n* Patients for interval-debulking, or for second- or third-look surgery, or palliative surgery planned.\n* Impossible to assess the resectability. Radiological signs suggesting complete resection is impossible.\n* Patients who have received more than two previous regimen of chemotherapy (maintenance is not considered a third regimen).\n* Third relapse or more.\n* Patients with second or other malignancies who have been treated by surgery, if the treatment might interfere with the treatment of relapsed ovarian cancer or if major impact on prognosis is expected.\n* Progression during chemotherapy or recurrence within 6 months after second-line platinum-based therapy\n* Any contradiction not allowing surgery and\u002For chemotherapy and\u002For or Niraparib\n* Accompanied by hypoxia serious chronic obstructive pulmonary disease\n* Uncontrolled hypertension, cerebrovascular accident\u002F Stroke, myocardial infarct, unstable angina, untreated thrombosis, chronic congestive heart failure, or serious arrhythmia in need of medicine.\n* Severe hepatitis, history of liver disease, nephrotic syndrome, renal insufficiency\n* Active ulcer history, abdominal wall fistula, perforation of gastrointestinal tract, or Intra-abdominal abscess, or simultaneously apply treatment\u002Fprevent ulcers therapy.\n* Uncontrolled diabetes\n* Uncontrolled epilepsy need long-term antiepileptic treatment.\n* Any medication induced considerable risk of surgery, e.g. estimated bleeding due to oral anticoagulating agents.\n* ≥3 grade anemia, neutropenia or thrombocytopenia due to chemotherapy, and lasted for more than 4 weeks\n* Patients with a known hypersensitivity to Niraparib or any of the excipients of the product.",{"count":634,"type":20},167,[23],"This is a Phase II, open-label, multicenter, randomized umbrella study to evaluate the efficacy of cytoreductive surgery and Niraparib maintenance in participants with platinum-sensitive secondary recurrent ovarian cancer. Cohort 1 will focus on participants without prior use of PARP inhibitor, and without prior secondary cytoreduction (SCR) when first recurrence. Cohort 2 will focus on participants with prior use of PARP inhibitor, but without prior SCR when first recurrence. Cohort 3 will focus on participants with SCR when first recurrence, but without prior use of PARP inhibitor.",[638,63,28],"Ovarian Cancer Recurrent",[640,641,642,643],"reurrent Ovarian Cancer","Secondary Cytoreductive Surgery","Chemotherapy","Niraparib maintenance","2022-03-04",{"date":646,"type":33},"2022-03-18",{"date":648,"type":33},"2019-10-18",{"date":650,"type":20},"2026-12",{"name":111,"class":112},{"id":653,"slug":654,"hasResults":11,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":21,"phases":661,"briefSummary":662,"conditions":663,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":41},"100426556","phase-2-a-study-of-maintenance-dcvacovca-after-first-line-chemotherapy-added-standard-of-care-100426556","NCT04834544","A Study of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added Standard of Care","A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC\u002FOvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.","Inclusion Criteria:\n\n1. Eighteen years of age or older at the time written informed consent is obtained\n2. Newly diagnosed, histologically confirmed FIGO stage III or IV EOC (high-grade serous or high-grade endometrioid)\n3. After primary debulking surgery or after interval debulking surgery; residual disease after surgery with optimal resection as R0 or R1 (R0 is defined as no macroscopic residual disease, R1 is defined as macroscopic residual disease with a maximal diameter of \\\u003C1 cm)\n4. Known BRCA status; if BRCA mutation status not known, results of BRCA testing must be available before randomization\n5. Laboratory criteria:\n\n   5.1. White blood cells \\>4000\u002Fmm3 (4.0×109\u002FL) 5.2. Neutrophil count \\>1500\u002Fmm3 (1.5×109\u002FL) 5.3. Hemoglobin ≥8 g\u002FdL (80 g\u002FL) 5.4. Platelet count ≥100,000\u002Fmm3 (100×109\u002FL) 5.5. Total bilirubin \\\u003C2× upper limit of normal (ULN) (benign hereditary hyperbilirubinemias, e.g., Gilbert's syndrome, are permitted) 5.6. Serum alanine aminotransferase, aspartate aminotransferase, and creatinine \\\u003C2×ULN 5.7. Blood urea nitrogen \\\u003C2×ULN\n6. Adequate coagulation parameters:\n\n   6.1. Activated partial thromboplastin time ≤1.5×ULN 6.2. International normalized ratio ≤1.5\n7. ECOG performance status 0-2\n8. Patients of child-bearing potential and their partners who are sexually active must agree to the use of 2 highly effective forms of contraception from the patient's signing of the ICF until 6 months after the last\u002Ffinal dose of first-line Pt-based adjuvant chemotherapy or IMP, whichever occurs later:\n\n   a. Condom with spermicide and one of the following:\n   * Oral contraceptive or hormonal therapy (e.g., hormone implants)\n   * Placement of an intra-uterine device (IUD)\n\n   Acceptable non-hormonal birth control methods include:\n   1. Total sexual abstinence from the patient's signing of the ICF until 6 months after the last\u002Ffinal dose of first-line Pt-based adjuvant chemotherapy or IMP, whichever occurs later\n   2. Vasectomized sexual partner plus male condom with spermicide and participant assurance that partner received post-vasectomy confirmation of azoospermia\n   3. Tubal occlusion plus male condom with spermicide\n   4. IUD plus male condom with spermicide. Provided coils are copper-banded.\n\n   Acceptable hormonal methods include:\n   1. Etonogestrel implants (e.g., Implanon, Norplan) plus male condom with spermicide\n   2. Normal and low dose combined oral pills plus male condom with spermicide\n   3. Norelgestromin\u002Fethinyl estradiol transdermal system plus male condom with spermicide\n   4. Intravaginal device plus male condom with spermicide (e.g., ethinyl estradiol and etonogestrel)\n   5. Cerazette (desogestrel) plus male condom with spermicide. Cerazette is currently the only highly efficacious progesterone-based pill.\n9. Signed informed consent and ability to comprehend its content\n\nExclusion Criteria:\n\n1. Non-epithelial ovarian carcinoma or mixed epithelial histology\n2. Borderline tumors (tumors of low malignant potential)\n3. First-line Pt-based adjuvant chemotherapy already started after surgery\n4. Intention to treat with intraperitoneal chemotherapy\n5. Previous or concurrent radiotherapy to the abdomen and pelvis\n6. Major surgery (with the exception of debulking surgery) within 3 weeks before informed consent signature or patient has not recovered from any effects of any major surgery\n7. Malignancy other than EOC, except malignancy that has been in complete remission for a minimum of 3 years and except carcinoma in situ of the cervix or non-melanoma skin carcinomas that have been definitively treated\n8. Use of any immunotherapy in the past (e.g., anti-PD-1\u002FPD-L1 or other immune checkpoint inhibitors, therapeutic vaccines, adoptive cell therapy, cytokines); in case of uncertainty, discuss with the medical monitor\n9. Symptomatic uncontrolled brain or leptomeningeal metastases. A scan to confirm the absence of brain metastases is not required. Patients with spinal cord compression may be considered if they have received definitive treatment for this and evidence of clinically stable disease for 28 days.\n10. Co-morbidities:\n\n    10.1. HIV positive 10.2. Active hepatitis B (HBV) and\u002For C (HCV), active syphilis 10.3. Evidence of active bacterial, viral, or fungal infection requiring systemic treatment 10.4. Clinically significant cardiovascular disease including: 10.4.1. Symptomatic congestive heart failure 10.4.2. Unstable angina pectoris 10.4.3. Severe cardiac arrhythmia requiring medication 10.4.4. Uncontrolled hypertension 10.4.5. Myocardial infarction or ventricular arrhythmia or stroke within a 6-month period before inclusion, ejection fraction \\\u003C40% or serious cardiac conduction system disorders, if a pacemaker is not present 10.5. Pericardial effusion of any CTCAE grade 10.6. Severe chronic obstructive pulmonary disease defined as grade C and D according to Global Initiative for Obstructive Lung Disease 10.7. Patients considered a poor medical risk due to other serious, uncontrolled medical disorders, non-malignant systemic diseases or active, uncontrolled infections 10.8. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study treatment, or is not in the best interest of the patient to participate 10.9. Active autoimmune disease requiring treatment 10.10. History of severe forms of primary immune deficiencies 10.11. History of anaphylaxis or other severe reactions following vaccination 10.12. Psychiatric or social conditions which, in the investigator's opinion, would prevent participation in the study\n11. Known hypersensitivity to any constituent of IMP\n12. Systemic immunosuppressive therapy for any reason (except inhaled \u002F intranasal steroids and short-term systemic steroids \\\u003C30 days duration and ≤10 mg prednisone-equivalent per day are allowed)\n13. Participation in a clinical trial using experimental therapy within the last 4 weeks before informed consent signature\n14. Pregnant or breast feeding, or expecting to conceive children within the projected duration of the study treatment\n15. Refusal to sign informed consent",{"count":660,"type":20},75,[23],"This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC\u002FOvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.",[664,26,28],"Epithelial Ovarian Carcinoma","2021-04-30",{"date":667,"type":33},"2021-05-03",{"date":669,"type":33},"2021-04-19",{"date":671,"type":20},"2027-04-20",{"name":673,"class":40},"Peking University Third Hospital",{"id":675,"slug":676,"hasResults":11,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":21,"phases":683,"briefSummary":684,"conditions":685,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":694},"100402080","phase-3-stratified-evaluation-of-pds-and-nact-ids-in-ovarian-cancer-focus-100402080","NCT04515602","Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)","Stratified Evaluation and Prediction of Survival Benefit for PDS or NACT-IDS in Advanced Ovarian Cancer, A Randomized, Phase 3 Trial After the SUNNY Study","For Part 1:\n\nInclusion Criteria:\n\n1. Females aged ≥ 18 years.\n2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (diagnosis by biopsy or core needle biopsy\\*, laparoscopic biopsy is not recommended). \\* If core needle biopsy could not be performed, patients should satisfy the following conditions:\n\n   1. the patient has a pelvic mass, and\n   2. omental cake or other metastasis larger than 2 cm in the upper abdomen, or pathologic confirmed extra-abdominal metastasis (FIGO IV), and\n   3. preoperative CA125\u002FCEA ratio \\> 25. If CA125\u002FCEA ratio ≤ 25, imaging or endoscopy is obligatory to exclude a primary gastric, colon, or breast carcinoma.\n3. cPCI score ≤ 8.\n4. Performance status (ECOG 0-2).\n5. Good ASA score (1\u002F2).\n6. Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery:\n\n   1. white blood cells \\>3,000\u002FµL, absolute neutrophil count ≥1,500\u002FµL, platelets ≥100,000\u002FµL, hemoglobin ≥9 g\u002FdL,\n   2. serum creatinine \\\u003C1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL\u002Fmin according to Cockroft-Gault formula or to local lab measurement,\n   3. serum bilirubin \\\u003C1.25 x UNL, AST(SGOT) and ALT(SGPT) \\\u003C2.5 x UNL.\n7. Comply with the study protocol and follow-up.\n8. Patients who have given their written informed consent.\n\nExclusion Criteria:\n\n1. Non-epithelial ovarian malignancies and borderline tumors.\n2. Low grade ovarian cancer.\n3. Mucinous ovarian cancer.\n4. cPCI score \\> 8.\n5. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or breast carcinoma (without any signs of relapse or activity).\n6. Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol.\n7. Other conditions, such as religious, psychological and other factors, that could interfere with provision of informed consent, compliance to study procedures, or follow-up.\n\nFor Part 2:\n\nInclusion Criteria:\n\n1. Females aged ≥ 18 years, and \\\u003C 70 years.\n2. Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma.\n3. cPCI score ≥ 10.\n4. For FIGO IVB patients, abdominal lesions should be confined to one lobe of liver parenchyma metastasis or splenic metastasis. All extra-abdominal metastases should be resectable, such as inguinal lymph nodes, solitary supraclavicular, retrocrural or paracardial nodes.\n5. Good performance status (ECOG 0-1).\n6. Good ASA score (1\u002F2).\n7. Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery.\n8. Comply with the study protocol and follow-up.\n9. Patients who have given their written informed consent.\n\nExclusion Criteria:\n\n1. Non-epithelial ovarian malignancies and borderline tumors.\n2. Low grade ovarian cancer.\n3. Mucinous ovarian cancer.\n4. Clear cell carcinoma.\n5. cPCI score \\\u003C 8.\n6. Lung metastasis, diffused pleural metastasis, bone metastasis, metastasis of mediastinal lymph node, internal mammary node, or multiple extra-peritoneal lymph nodes.\n7. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ or breast carcinoma (without any signs of relapse or activity).\n8. Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise the adherence to the protocol.\n9. Other conditions, such as religious, psychological and other factors, that could interfere with provision of informed consent, compliance to study procedures, or follow-up.",{"count":682,"type":20},410,[124],"The purpose of this study is to answer the fundamental question 'The Optimal Timing of Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform translational study.",[62,63,28],"2020-08-25",{"date":688,"type":33},"2020-08-27",{"date":690,"type":20},"2021-01",{"date":692,"type":20},"2028-01",{"name":111,"class":112},4]